Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3042981 | 0.76 | SIRT2 (0.36) | ESR1ESR2MGAT2KDM4EALDH1A1 | |
| Ethylene SCHEMBL11125086 | 0.73 | SIRT2 (0.34) | ESR1ESR2MGAT2CYP19A1 | |
| SCHEMBL17106400 | 0.71 | ESR1 (0.31) | ESR1ESR2 | |
| SCHEMBL10581734 | 0.71 | ALDH1A1 (0.38) | MGAT2ALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL17106398 | 0.71 | ESR1 (0.31) | ESR1ESR2 | |
| SCHEMBL871021 | 0.70 | — | — | |
| SCHEMBL3413093 | 0.70 | TSHR (0.35) | MGAT2GAANPC1MTORRAB9A | |
| SCHEMBL23572529 | 0.68 | TSHR (0.36) | GAANPC1MTORRAB9ATSHR | |
| SCHEMBL24308962 | 0.68 | TSHR (0.36) | GAANPC1MTORRAB9ATSHR | |
| SCHEMBL7171314 | 0.67 | NPC1 (0.32) | NPC1MTORRAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, HTR1D, RXFP1 | HSD17B10 1498/4885ESR1 3581/4885ESR2 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.